Dr. Tingchao Zhang, CEO of DeJin Medical, Selected for Hangzhou's 'West Lake Pearl Project' Talent Program

Recently, Dr. Tingchao Zhang, Director and General Manager of Valgen Medtech, successfully入选 the "West Lake Pearl Project" talent in Hangzhou with his profound professional expertise and forward-looking industrial layout in the field of cardiac interventional therapy.

This is not only an accolade for Dr. Zhang Tingchao's personal academic and management capabilities, but also a significant recognition that the path he and Valgen Medtech, which he leads, have steadfastly pursued—focusing on innovation in "deep waters" and upholding the long-term clinical value through practical efforts—has gained high attention and approval.

As a Ph.D. and doctoral supervisor in the Materials and Chemical Engineering program at Sichuan University, Dr. Tingchao Zhang has always stood at the intersection of research and clinical practice, deeply cultivating the cardiovascular field for nearly 20 years. He has led the development of multiple products certified by CE, FDA, and NMPA, and his profound understanding and implementation of global standards have...The underlying characteristic of Valgen Medtech, led by him, isProfessional, reliable, and able to withstand the most stringent scrutiny.

Under the guidance of Dr. Zhang Tingchao's "pursuit of truth and pragmatism," every step taken by Valgen Medtech follows a clear logic: starting from the mission of "providing safer and more effective solutions for heart disease patients," with the precision technology symbolized by "DragonFly" and the ambition to propel China's high-end medical industry to new heights as its dual wings, it is determined to make Chinese innovation a globally leading force. This dedication ensures that Valgen Medtech never pursues short-term publicity but instead focuses on building sustainable, systematic capabilities.

This development determination has been transformed into verifiable results: Valgen Medtech has not only become an industry benchmark frequently recognized by official authorities, but also demonstrated continuous growth in the market. In 2024, its core product DragonFly™ will be launched; in 2025, Valgen Medtech will receive the National Science and Technology Progress Award and successively be named as a "Gazelle" enterprise, a "New Power" enterprise, and a Hangzhou Enterprise Technology Center.

The light of "West Lake Pearl" has set a clear footnote for the course led by Dr. Zhang Tingchao and Valgen Medtech. In the future, under his leadership, we will continue to uphold the professionalism, rigor, and pragmatic pursuit that run through our veins, ensuring that every innovation originating from China reliably reaches patients worldwide, honoring every life entrusted to us and safeguarding every heartbeat.